Literature DB >> 18353661

Study of subcellular localization and proteolysis of ataxin-3.

Chiara Pozzi1, Marco Valtorta, Gabriella Tedeschi, Elena Galbusera, Valentina Pastori, Alessandra Bigi, Simona Nonnis, Eleonora Grassi, Paola Fusi.   

Abstract

In this work we investigate subcellular localization and proteolytic cleavage of different forms of ataxin-3 (AT-3), the protein responsible for spinocerebellar ataxia type 3. Normal (AT-3Q6 and AT-3Q26) and pathological (AT-3Q72) ataxins-3, as well as two truncated forms lacking poly-Q, were studied. Full-length proteins were also expressed as C14A mutants, in order to assess whether AT-3 autoproteolytic activity was involved in its fragmentation. We found that both normal and pathological proteins localized in the cytoplasm and in the nucleus, as expected, but also in the mitochondria. Microsequencing showed that all ataxins-3 underwent the same proteolytic cleavage, removing the first 27 amino acids. Interestingly, while normal ataxins were further cleaved at a number of caspase sites, pathological AT-3 was proteolyzed to a much lesser extent. This may play a role in the pathogenesis, hampering degradation of aggregation-prone expanded AT-3. In addition, autolytic cleavage was apparently not involved in AT-3 proteolysis.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18353661     DOI: 10.1016/j.nbd.2008.01.011

Source DB:  PubMed          Journal:  Neurobiol Dis        ISSN: 0969-9961            Impact factor:   5.996


  27 in total

Review 1.  Toward understanding Machado-Joseph disease.

Authors:  Maria do Carmo Costa; Henry L Paulson
Journal:  Prog Neurobiol       Date:  2011-11-23       Impact factor: 11.685

2.  Divalproex sodium modulates nuclear localization of ataxin-3 and prevents cellular toxicity caused by expanded ataxin-3.

Authors:  Zi-Jian Wang; Aoife Hanet; Daniel Weishäupl; Inês M Martins; Anna S Sowa; Olaf Riess; Thorsten Schmidt
Journal:  CNS Neurosci Ther       Date:  2018-01-09       Impact factor: 5.243

Review 3.  A Futile Battle? Protein Quality Control and the Stress of Aging.

Authors:  Ryo Higuchi-Sanabria; Phillip Andrew Frankino; Joseph West Paul; Sarah Uhlein Tronnes; Andrew Dillin
Journal:  Dev Cell       Date:  2018-01-22       Impact factor: 12.270

4.  Physiological and pathophysiological characteristics of ataxin-3 isoforms.

Authors:  Daniel Weishäupl; Juliane Schneider; Barbara Peixoto Pinheiro; Corinna Ruess; Sandra Maria Dold; Felix von Zweydorf; Christian Johannes Gloeckner; Jana Schmidt; Olaf Riess; Thorsten Schmidt
Journal:  J Biol Chem       Date:  2018-11-19       Impact factor: 5.157

5.  Ubiquitination regulates the neuroprotective function of the deubiquitinase ataxin-3 in vivo.

Authors:  Wei-Ling Tsou; Aaron A Burr; Michelle Ouyang; Jessica R Blount; K Matthew Scaglione; Sokol V Todi
Journal:  J Biol Chem       Date:  2013-10-08       Impact factor: 5.157

Review 6.  Mutant Ataxin-3-Containing Aggregates (MATAGGs) in Spinocerebellar Ataxia Type 3: Dynamics of the Disorder.

Authors:  Kritika Raj; Ravi Shankar Akundi
Journal:  Mol Neurobiol       Date:  2021-02-24       Impact factor: 5.590

7.  The emerging role of proteolysis in mitochondrial quality control and the etiology of Parkinson's disease.

Authors:  Riya Shanbhag; Guang Shi; Jarungjit Rujiviphat; G Angus McQuibban
Journal:  Parkinsons Dis       Date:  2012-05-13

8.  Cerebellar soluble mutant ataxin-3 level decreases during disease progression in Spinocerebellar Ataxia Type 3 mice.

Authors:  Huu Phuc Nguyen; Jeannette Hübener; Jonasz Jeremiasz Weber; Stephan Grueninger; Olaf Riess; Andreas Weiss
Journal:  PLoS One       Date:  2013-04-23       Impact factor: 3.240

9.  Preventing Ataxin-3 protein cleavage mitigates degeneration in a Drosophila model of SCA3.

Authors:  Joonil Jung; Kexiang Xu; Derek Lessing; Nancy M Bonini
Journal:  Hum Mol Genet       Date:  2009-09-25       Impact factor: 6.150

10.  Autophagy induction reduces mutant ataxin-3 levels and toxicity in a mouse model of spinocerebellar ataxia type 3.

Authors:  Fiona M Menzies; Jeannette Huebener; Maurizio Renna; Michael Bonin; Olaf Riess; David C Rubinsztein
Journal:  Brain       Date:  2009-12-09       Impact factor: 13.501

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.